AbbVie (ABBV) reached $187.12 at the closing of the latest trading day, reflecting a +1.23% change compared to its last close.
I maintain my Buy rating on AbbVie, emphasizing its medium-to-long-term potential despite recent outlook downgrades and tariff risks. Recent guidance cuts are minor and don't meaningfully undermine the investment case; with earnings growth expected in Q2 2025. The company's dividends add to its attractiveness at an uncertain time, adding to robust price returns over time.
ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.
![]() ABBV 3 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 6 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 9 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 15 Jul 2024 Paid | Quarterly | $1.55 Per Share |
![]() ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
23 Jul 2025 23 Jul 2025 Date | | 3.22 Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
![]() ABBV 3 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 6 months ago Paid | Quarterly | $1.64 Per Share |
![]() ABBV 9 months ago Paid | Quarterly | $1.55 Per Share |
![]() ABBV 15 Jul 2024 Paid | Quarterly | $1.55 Per Share |
![]() ABBV 12 Apr 2024 Paid | Quarterly | $1.55 Per Share |
23 Jul 2025 23 Jul 2025 Date | | 3.22 Cons. EPS | - EPS |
24 Apr 2025 Date | | - Cons. EPS | - EPS |
31 Jan 2025 Date | | 2.26 Cons. EPS | 2.16 EPS |
30 Oct 2024 Date | | 2.92 Cons. EPS | 3 EPS |
25 Oct 2024 Date | | 2.95 Cons. EPS | - EPS |
Drug Manufacturers - General Industry | Healthcare Sector | Robert A. Michael CPA CEO | XSGO Exchange | US00287Y1091 ISIN |
US Country | 55,000 Employees | 15 Apr 2025 Last Dividend | - Last Split | 2 Jan 2013 IPO Date |
AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.